Altrius Capital Management’s Novartis NVS Stock Holding History

Altrius Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4M	Buy	72,584 +1,953	+3%	+$293K	2.16%	5
2026 Q1	$10.8M	Sell	70,631 -4,292	-6%	-$658K	2.15%	6
2025 Q4	$10.3M	Buy	74,923 +494	+0.7%	+$64.7K	2.19%	4
2025 Q3	$9.54M	Sell	74,429 -4,480	-6%	-$547K	2.18%	6
2025 Q2	$9.55M	Sell	78,909 -703	-0.9%	-$79.2K	2.23%	5
2025 Q1	$8.88M	Buy	79,612 +1,829	+2%	+$195K	2.16%	7
2024 Q4	$7.57M	Buy	77,783 +3,345	+4%	+$357K	2.03%	9
2024 Q3	$8.56M	Sell	74,438 -3,622	-5%	-$411K	2.15%	8
2024 Q2	$8.31M	Buy	78,060 +1,339	+2%	+$134K	2.19%	5
2024 Q1	$7.42M	Buy	76,721 +6,913	+10%	+$709K	1.87%	17
2023 Q4	$7.05M	Sell	69,808 -220	-0.3%	-$21.2K	1.96%	10
2023 Q3	$7.13M	Sell	70,028 -506	-0.7%	-$51.4K	2.12%	8
2023 Q2	$7.12M	Sell	70,534 -728	-1%	-$72.8K	2.11%	9
2023 Q1	$6.56M	Buy	71,262 +3,978	+6%	+$347K	2%	16
2022 Q4	$6.1M	Buy	67,284 +2,147	+3%	+$181K	1.92%	12
2022 Q3	$4.95M	Buy	65,137 +16,108	+33%	+$1.34M	1.89%	7
2022 Q2	$4.14M	Buy	+49,029	New	+$4.3M	1.35%	34

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Altrius Capital Management's NVS Position: Q2 2026 in Review

Altrius Capital Management increased its Novartis (NVS) stake by 2.8% in Q2 2026, buying an estimated $293K and bringing the position to 72,584 shares worth $11.4M. The position accounts for 2.16% of the portfolio, ranked #5.

Altrius Capital Management first reported a position in NVS in Q2 2022 and has held it in 17 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Altrius Capital Management held 72,584 shares of Novartis worth $11.4M as of Q2 2026.
Altrius Capital Management bought 1,953 Novartis shares in Q2 2026, an estimated $293K.
Novartis made up 2.16% of Altrius Capital Management's portfolio in Q2 2026, its #5 holding.
Altrius Capital Management first reported a position in Novartis in Q2 2022 and has held it in 17 quarters since.
1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Altrius Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.